| Characteristic . | Value . |
|---|---|
| Male | 65 |
| Subtype B | 56 |
| Median time since HIV-1 diagnosis, years (IQR) | 15.7 (6.74–22.4) |
| Median duration of current INSTI regimen, months (IQR) | 10.7 (5.7–30) |
| Median baseline plasma HIV-1 RNA, log10 copies/mL (IQR) | 3.1 (1.9–4.9) |
| Pre-INSTI VL (copies/mL) | |
| <50 | 42.3 |
| 50–100 000 | 42.6 |
| >100 000 | 15.1 |
| Median baseline CD4 cell count/mm3 (IQR) | 371 (173–649) |
| CD4 baseline <200 cells | 32.3 |
| Median failure plasma HIV-1 RNA, log10 copies/mL (IQR) | 2.9 (2.3–4) |
| Median failure CD4 cell count/mm3 (IQR) | 418 (223–670) |
| INSTI co-treatment (%) | |
| NRTIs | 55.3 |
| NRTI + PI | 13.2 |
| NNRTIs | 7 |
| PIs | 5.6 |
| NNRTI + PI | 4.9 |
| NRTI + NNRTI | 3.8 |
| other | 8.7 |
| GSS (%) | |
| 0–0.5 | 16.11 |
| 1–1.5 | 27.22 |
| 2–2.5 | 44.07 |
| ≥3 | 12.59 |
| Characteristic . | Value . |
|---|---|
| Male | 65 |
| Subtype B | 56 |
| Median time since HIV-1 diagnosis, years (IQR) | 15.7 (6.74–22.4) |
| Median duration of current INSTI regimen, months (IQR) | 10.7 (5.7–30) |
| Median baseline plasma HIV-1 RNA, log10 copies/mL (IQR) | 3.1 (1.9–4.9) |
| Pre-INSTI VL (copies/mL) | |
| <50 | 42.3 |
| 50–100 000 | 42.6 |
| >100 000 | 15.1 |
| Median baseline CD4 cell count/mm3 (IQR) | 371 (173–649) |
| CD4 baseline <200 cells | 32.3 |
| Median failure plasma HIV-1 RNA, log10 copies/mL (IQR) | 2.9 (2.3–4) |
| Median failure CD4 cell count/mm3 (IQR) | 418 (223–670) |
| INSTI co-treatment (%) | |
| NRTIs | 55.3 |
| NRTI + PI | 13.2 |
| NNRTIs | 7 |
| PIs | 5.6 |
| NNRTI + PI | 4.9 |
| NRTI + NNRTI | 3.8 |
| other | 8.7 |
| GSS (%) | |
| 0–0.5 | 16.11 |
| 1–1.5 | 27.22 |
| 2–2.5 | 44.07 |
| ≥3 | 12.59 |
Values are expressed as percentages unless otherwise indicated.
| Characteristic . | Value . |
|---|---|
| Male | 65 |
| Subtype B | 56 |
| Median time since HIV-1 diagnosis, years (IQR) | 15.7 (6.74–22.4) |
| Median duration of current INSTI regimen, months (IQR) | 10.7 (5.7–30) |
| Median baseline plasma HIV-1 RNA, log10 copies/mL (IQR) | 3.1 (1.9–4.9) |
| Pre-INSTI VL (copies/mL) | |
| <50 | 42.3 |
| 50–100 000 | 42.6 |
| >100 000 | 15.1 |
| Median baseline CD4 cell count/mm3 (IQR) | 371 (173–649) |
| CD4 baseline <200 cells | 32.3 |
| Median failure plasma HIV-1 RNA, log10 copies/mL (IQR) | 2.9 (2.3–4) |
| Median failure CD4 cell count/mm3 (IQR) | 418 (223–670) |
| INSTI co-treatment (%) | |
| NRTIs | 55.3 |
| NRTI + PI | 13.2 |
| NNRTIs | 7 |
| PIs | 5.6 |
| NNRTI + PI | 4.9 |
| NRTI + NNRTI | 3.8 |
| other | 8.7 |
| GSS (%) | |
| 0–0.5 | 16.11 |
| 1–1.5 | 27.22 |
| 2–2.5 | 44.07 |
| ≥3 | 12.59 |
| Characteristic . | Value . |
|---|---|
| Male | 65 |
| Subtype B | 56 |
| Median time since HIV-1 diagnosis, years (IQR) | 15.7 (6.74–22.4) |
| Median duration of current INSTI regimen, months (IQR) | 10.7 (5.7–30) |
| Median baseline plasma HIV-1 RNA, log10 copies/mL (IQR) | 3.1 (1.9–4.9) |
| Pre-INSTI VL (copies/mL) | |
| <50 | 42.3 |
| 50–100 000 | 42.6 |
| >100 000 | 15.1 |
| Median baseline CD4 cell count/mm3 (IQR) | 371 (173–649) |
| CD4 baseline <200 cells | 32.3 |
| Median failure plasma HIV-1 RNA, log10 copies/mL (IQR) | 2.9 (2.3–4) |
| Median failure CD4 cell count/mm3 (IQR) | 418 (223–670) |
| INSTI co-treatment (%) | |
| NRTIs | 55.3 |
| NRTI + PI | 13.2 |
| NNRTIs | 7 |
| PIs | 5.6 |
| NNRTI + PI | 4.9 |
| NRTI + NNRTI | 3.8 |
| other | 8.7 |
| GSS (%) | |
| 0–0.5 | 16.11 |
| 1–1.5 | 27.22 |
| 2–2.5 | 44.07 |
| ≥3 | 12.59 |
Values are expressed as percentages unless otherwise indicated.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
